MUC17 Is a Potential New Prognostic Biomarker and Promotes Pancreatic Cancer Progression in Obstructive Jaundice
Oncology · 2024
DOI: 10.1159/000541874 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oncology, 2024. Verfasst von Eleonóra Gál und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Pharmacotherapy, University of Szeged, Szeged, Hungary. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Biomarkers, Tumor, Jaundice, Obstructive, Mucins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
Our working group has previously shown that bile acids (BAs) accelerate carcinogenic processes in pancreatic cancer (PC) in which mucin 4 (MUC4) expression has a central role. However, the role of other mucins in PC is less clear, especially in bile-induced cancer progression. The study aim was to investigate expression of MUC17 in BA- or human serum-treated pancreatic ductal adenocarcinoma (PDAC) cell lines.
Methods
Different cell-based assays with RNA silencing/overexpression were used to study the role of MUC17 in cancer progression. Protein expression of MUC17 was evaluated in 55 human pancreatic samples by immunohistochemistry, and Kaplan-Meier survival analysis was used to compare survival curves.
Results
Expression of MUC17 increased in PDAC patients, especially in obstructive jaundice (OJ), and the elevated MUC17 expression associated with poorer overall survival (10.66 ± 1.99 vs. 15.05 ± 2.03 months; log-rank: 0.0497). Treatment of Capan-1 and AsPC-1 cells with BAs or with human serum obtained from PDAC + OJ patients enhanced the expression of MUC17, as well as the proliferative potential of the cells, whereas knockdown of MUC17 alone or in combination with MUC4 decreased BAs-induced carcinogenic processes.
Conclusion
Our results demonstrated that MUC17 has a central role in bile-induced PC progression, and in addition to MUC4, this isoform also can be used as a novel prognostic biomarker.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology and Pharmacotherapy, University of Szeged, Szeged, Hungary.
- Regenerative Medicine and Cellular Pharmacology Research Laboratory, Department of Dermatology and Allergology, University of Szeged, Szeged, Hungary.
- HCEMM SZTE Skin Research Group, University of Szeged, Szeged, Hungary.
- Department of Pathology, University of Szeged, Szeged, Hungary.
- Department of Biochemistry, University of Szeged, Szeged, Hungary.
- Department of Microbiology, University of Szeged, Szeged, Hungary.
Zitieren
APA
Gál, E., Menyhárt, I., Veréb, Z., Kemény, L., Tiszlavicz, L., Köhler, Z. M., Keller-Pintér, A., Rakk, D., Szekeres, A., Takács, T., Czakó, L., Hegyi, P., Yosef, B., & Venglovecz, V. (2024). MUC17 Is a Potential New Prognostic Biomarker and Promotes Pancreatic Cancer Progression in Obstructive Jaundice. Oncology. https://doi.org/10.1159/000541874
Vancouver
Gál E, Menyhárt I, Veréb Z, Kemény L, Tiszlavicz L, Köhler ZM, et al. MUC17 Is a Potential New Prognostic Biomarker and Promotes Pancreatic Cancer Progression in Obstructive Jaundice. Oncology. 2024. doi:10.1159/000541874
BibTeX
@article{Gl2024,
author = {Gál, Eleonóra and Menyhárt, István and Veréb, Zoltán and Kemény, Lajos and Tiszlavicz, László and Köhler, Zoltán Márton and Keller-Pintér, Anikó and Rakk, Dávid and Szekeres, András and Takács, Tamás and Czakó, László and Hegyi, Péter and Yosef, Boshra and Venglovecz, Viktória},
title = {MUC17 Is a Potential New Prognostic Biomarker and Promotes Pancreatic Cancer Progression in Obstructive Jaundice},
journal = {Oncology},
year = {2024},
doi = {10.1159/000541874}
}
EUVIMED